Gain Therapeutics’ (GANX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $8.00 price objective on the stock.

GANX has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Friday, September 4th. BTIG Research restated a “buy” rating and set a $5.00 target price on shares of Gain Therapeutics in a report on Tuesday, August 11th. Finally, Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Gain Therapeutics Stock Performance

GANX stock opened at $1.67 on Monday. Gain Therapeutics has a 1-year low of $1.53 and a 1-year high of $4.34. The business has a 50-day moving average price of $1.83 and a 200 day moving average price of $1.83. The company has a market capitalization of $72.88 million, a P/E ratio of -3.34 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. As a group, equities research analysts forecast that Gain Therapeutics will post -0.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Potomac Capital Management Inc. purchased a new position in Gain Therapeutics during the 4th quarter worth $3,252,000. GSA Capital Partners LLP acquired a new position in Gain Therapeutics during the 2nd quarter valued at about $1,283,000. BlackRock Inc. purchased a new stake in Gain Therapeutics in the second quarter valued at about $558,000. Squarepoint Ops LLC purchased a new stake in Gain Therapeutics in the second quarter valued at about $277,000. Finally, HighTower Advisors LLC acquired a new stake in Gain Therapeutics in the second quarter worth about $35,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. Its research focuses on correcting the activity of misfolded or dysfunctional lysosomal enzymes, which are implicated in conditions involving the accumulation of toxic cellular material.

The company uses a structure-based drug discovery platform designed to identify previously unrecognized binding sites on disease-related proteins.